HGFR/c-MET Antibody (Metheresis patent anti-Met) - Humanized

• Reactivity: Hu
• Applications: ELISA, Flow, Func
• Clone: Metheresis patent anti-Met
• Clonality: Monoclonal
• Host: Human
• Conjugate: Unconjugated
• Concentration: LYOPH

HGFR/c-MET Antibody (Metheresis patent anti-Met) - Humanized Summary

• Description: Expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
  
  Upon receipt, store immediately at -20C or lower for 24 months in a lyophilized state. - 80C for 3 months after reconstitution. Avoid repeated freeze-thaw cycles.
• Additional Information: Recombinant Monoclonal Antibody
• Immunogen: HGFR / c-Met
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Human
• Gene: MET
• Purity: Protein A purified
• Endotoxin Note: < 0.001EU/ug,determined by LAL method.

Applications/Dilutions

• Dilutions:
  • ELISA
  • Flow Cytometry
  • Functional

Packaging, Storage & Formulations

• Storage: Store at -20C in powder form. Store at -80C once reconstituted.
• Buffer: Lyophilized from 25mM histidine, 8% sucrose, 0.01% Tween80 (pH6.2)
• Preservative: No Preservative
• Concentration: LYOPH
• Purity: Protein A purified
• Reconstitution Instructions: Reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

Alternate Names for HGFR/c-MET Antibody (Metheresis patent anti-Met) - Humanized

• AUTS9
• cMET
• c-MET
• EC 2.7.10
• EC 2.7.10.1
• hepatocyte growth factor receptor
• HGF R
• HGF receptor
• HGF/SF receptor
• HGFR
• Met (c-Met)
• met proto-oncogene (hepatocyte growth factor receptor)
• met proto-oncogene tyrosine kinase
• MET
• oncogene MET
• Proto-oncogene c-Met
• RCCP2
• Scatter factor receptor
• SF receptor
• Tyrosine-protein kinase Met

Background

Met is a receptor protein-tyrosine kinase (RPTK) for hepatocyte growth factor (HGF), which is a multifunctional cytokine controlling cell growth, morphogenesis, and motility. Met overexpression has been identified in a variety of human cancers (1). Met kinase domain possesses unique features that distinguish met from other members of the src family of protein tyrosine kinases. These results also demonstrate that the product of the activated met gene is a fusion protein and that the amino terminal end of this fusion protein exhibits homology to laminin B1 (2). Data suggest that RanBP9, functioning as an adaptor protein for the Met tyrosine kinase domain, can augment the HGF-Met signaling pathway and that RanBP9 overexpression may cause constitutive activation of the Ras signaling pathway (1). Hereditary papillary renal carcinoma (HPRC) is a recently recognized form of inherited kidney cancer Results suggest that missense mutations located in the MET proto-oncogene lead to constitutive activation of the Met protein and papillary renal carcinomas (3)

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: MET
• Uniprot:
  • P08581()